Biomarker testing in suspected pre-eclampsia

Hypertensive disorders, such as pre-eclampsia (PE), affect approximately 13.5% of pregnancies in the UK, which equates to around 80,000 women. Uncertainty in diagnosis of, and prognosis in, PE may lead to late diagnosis or, more frequently, unnecessary hospitalisation of women who do not go on to develop the condition. Therefore, there is an unmet medical need for short-term prediction or rule-out of the condition in pregnant women with suspected PE. A disease-specific biomarker accurately predicting maternal and neonatal complications in suspected PE cases would facilitate the decision-making of clinicians regarding monitoring and treatment.

This story is Premium Content and is only available to registered users. If you don't already have an account, please register with us completely free of charge.
 

Other news

Upcoming Events

Managing Difficult People

Holiday Inn, Kensington Forum, 97 Cromwell Road, London SW7 4DN
15 November 2018

War on Cancer 2018

The Waldorf Hilton, Aldwych, London WC2B 4DD
20 November 2018

Organisational Leadership Skills

Holborn, London
22-23 November 2018

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Oct 2018

High-throughput HPV testing: NHSCSP approval secured

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.